Cybin Closes Fiscal Year 2022, Reports Financial Results And Major Achievements

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biopharma company focused on progressing “psychedelics to therapeutics” through proprietary drug discovery platforms announced its financial and business results ended March 31, 2022.

The monetary assessment (in Canadian dollars) showed:

  • Cash and cash equivalents totaled C$53.6 million. 

  • Cash-based operating expenses equaled C$13.0 million for the quarter, of which C$3.8 million were one-time, non-recurring costs. Non-cash expenses summed C$5.1 million for a net loss of C$18.1 million.

  • Cash-based operating expenses added up to C$45.8 million for the year, of which C$11.6 were one-time, non-recurring costs. Non-cash expenses totaled C$21.8 million for a net loss of C$67.6 million.

  • Cash flows used in operating activities were C$9.7 million for …

Full story available on Benzinga.com

More Cybin Closes Fiscal Year 2022, Reports Financial Results And Major Achievements